Hagens Berman Opens Securities Fraud Probe Into CVRx After 59% Plunge
CVRX sits 42% above its 52-week low of $2.2 on elevated volume (2.6× avg).
Summary
Hagens Berman, a national securities law firm, announced an investigation into CVRx for potential securities fraud. The probe follows the company's August 6 disclosures of a DOJ Civil Investigative Demand, severe revenue guidance cuts, sales force disruption, and a collapse in Medicare Advantage approval rates from 80% to 25% within 30 days. The stock fell 59% on August 7. The firm is also examining whether the August 10 termination of Chief Revenue Officer Robert John is connected to the DOJ inquiry. This adds a new legal overhang to an already battered stock, and the investigation could lead to a class action lawsuit. The DOJ CID and the abrupt CRO departure suggest deeper operational and compliance issues than previously disclosed.
At the time of this announcement, CVRX was trading at $3.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.4M. The 52-week trading range was $2.20 to $11.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.